



Distribution: As Appendix 1

From: Chief Pharmaceutical Officer, Andrew Evans

Date: 25 February 2022

Reference: CEM/CPhA/2022/10

Category: Immediate – Action within 24 hours

Title: Covid-19 Therapeutic Alert: Remdesivir for patients hospitalised with COVID-19 (adults and children aged 12 years and older)

This guidance updates and replaces the COVID-19 Therapeutic Alert CEM//CPhA/2021/15, which was published on 15 June 2021.

For Action and information by:

- Chief Pharmacists
- Medical Directors

Issue:

The published policy has been updated to reflect the latest available information on the use of remdesivir in patients admitted to hospital due to COVID-19. A graphical clinical guide (attached below), summarising the main COVID treatment options available to this patient cohort, is also provided to support clinical decision making.

The updated policy provides links to the two other published clinical access policies supporting the use of remdesivir in patients with hospital-onset COVID infection, and non-hospitalised patients at highest risk from COVID infection, respectively.

The attached revised policy document and clinical pathway provide further detail and highlight required actions:

- Interim Clinical Commissioning Policy – Version 4 – 24 February 2022
- Clinical pathway: Therapies for patients hospitalised due to COVID-19

Send to:

Chief Executives of Health Boards
Medical Directors of Health Boards
Nurse Directors Health Boards
Directors of Public Health
Health Board Chief Pharmacists
Hospital Chief Pharmacists
PHW Consultants in Pharmaceutical Public Health
Chief Executives of NHS Trusts
Principal Pharmacist Welsh Quality Control
Principal Pharmacist Welsh Medicines Information Centre
AWTTC
NHS Direct

Welsh Government:

Chief Medical Officer
Chief Nursing Officer
Chief Scientific Officer
Director General Health and Social Services Group
Emergency Planning Adviser
Deputy Director Primary Care
Director Primary Care & Innovation
HSSG Comms
NHS Procurement Specialists